Form 8-K

8-K — MAXCYTE, INC.

Accession: 0001104659-26-059399

Filed: 2026-05-12

Period: 2026-05-12

CIK: 0001287098

SIC: 8731 (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — mxct-20260512x8k.htm (Primary)

EX-99.1 (mxct-20260512xex99d1.htm)

EX-99.2 (mxct-20260512xex99d2.htm)

GRAPHIC (mxct-20260512xex99d1001.jpg)

GRAPHIC (mxct-20260512xex99d2g001.jpg)

GRAPHIC (mxct-20260512xex99d2g002.jpg)

GRAPHIC (mxct-20260512xex99d2g003.jpg)

GRAPHIC (mxct-20260512xex99d2g004.jpg)

GRAPHIC (mxct-20260512xex99d2g005.jpg)

GRAPHIC (mxct-20260512xex99d2g006.jpg)

GRAPHIC (mxct-20260512xex99d2g007.jpg)

GRAPHIC (mxct-20260512xex99d2g008.jpg)

GRAPHIC (mxct-20260512xex99d2g009.jpg)

GRAPHIC (mxct-20260512xex99d2g010.jpg)

GRAPHIC (mxct-20260512xex99d2g011.jpg)

GRAPHIC (mxct-20260512xex99d2g012.jpg)

GRAPHIC (mxct-20260512xex99d2g013.jpg)

GRAPHIC (mxct-20260512xex99d2g014.jpg)

GRAPHIC (mxct-20260512xex99d2g015.jpg)

GRAPHIC (mxct-20260512xex99d2g016.jpg)

GRAPHIC (mxct-20260512xex99d2g017.jpg)

GRAPHIC (mxct-20260512xex99d2g018.jpg)

GRAPHIC (mxct-20260512xex99d2g019.jpg)

GRAPHIC (mxct-20260512xex99d2g020.jpg)

GRAPHIC (mxct-20260512xex99d2g021.jpg)

GRAPHIC (mxct-20260512xex99d2g022.jpg)

GRAPHIC (mxct-20260512xex99d2g023.jpg)

GRAPHIC (mxct-20260512xex99d2g024.jpg)

GRAPHIC (mxct-20260512xex99d2g025.jpg)

GRAPHIC (mxct-20260512xex99d2g026.jpg)

GRAPHIC (mxct-20260512xex99d2g027.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: mxct-20260512x8k.htm · Sequence: 1

MaxCyte, Inc._May 12, 2026

0001287098false00012870982026-05-122026-05-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2026

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40674

52-2210438

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

9713 Key West Avenue, Suite 400

Rockville, Maryland 20850

(Address of principal executive offices, including zip code)

(301) 944-1700

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.01 par value

MXCT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 12, 2026, MaxCyte, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On May 12, 2026, the Company posted an updated corporate presentation, which the Company may use from time to time in communications or conferences, to its website at https://investors.maxcyte.com. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.2 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Exhibit Description

99.1

Press Release, dated May 12, 2026

99.2

Corporate Presentation, dated May 2026

104

Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MaxCyte, Inc.

Dated: May 12, 2026

By:

/s/ Parmeet Ahuja

Parmeet Ahuja

Chief Financial Officer

EX-99.1

Filename: mxct-20260512xex99d1.htm · Sequence: 2

Exhibit 99.1

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue

Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million

MaxCyte’s Board authorized a $10 million share repurchase program

ROCKVILLE, MD, May 12, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.

“We are pleased with our performance in the first quarter, and remain confident in our full year guidance,” said Maher Masoud, President and CEO of MaxCyte. “Our core revenue from partners and customers was in line with our expectations for both our ExPERT electroporation platforms and SeQure services. The SPL portfolio continues to advance in the clinic, including a clinical customer that began dosing patients in a registrational study in the first quarter, and we remain confident additional customers will initiate registrational trials this year. Further, our SPL portfolio remains strong and spans a broad range of modalities and indications. MaxCyte remains extremely well positioned in the cell & gene therapy industry, with leading technology and an efficient cost structure. Reflecting continued confidence in our strategy and the long-term value of our business, the Board today authorized a $10 million share repurchase. This authorization provides us with flexibility in capital allocation while we continue to invest in key growth initiatives, including the recent launch of ExPERT DTx and the integration of SeQure Dx. We believe this balanced approach enables us to both reinvest in the business and return capital to shareholders.”

First Quarter Financial Results

Total revenue of $9.7 million in the first quarter of 2026, a decrease of 7% over the first quarter of 2025.

Core business revenue of $6.2 million in the first quarter of 2026, a decrease of 25% over the first quarter of 2025.

Strategic Platform License (SPL) Program-related revenue was $3.4 million for the first

quarter of 2026, compared to $2.1 million in the first quarter of 2025.

Gross profit for the first quarter of 2026 was $8.1 million (84% gross margin), compared to $8.9 million (86% gross margin) in the first quarter of 2025.

Non-GAAP adjusted gross margin was 78% when excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 83% in the first quarter of 2025.

Operating expenses for the first quarter of 2026 were $14.3 million, compared to operating expenses of $21.2 million in the first quarter of 2025.

First quarter 2026 net loss was $4.8 million compared to net loss of $10.3 million for the same period in 2025.

EBITDA, a non-GAAP measure, was a loss of $5.1 million for the first quarter of 2026, compared to a loss of $11.2 million for the first quarter of 2025; stock-based compensation expense was $1.1 million in the first quarter of 2026 compared to $3.0 million in the first quarter of 2025.

Total SPL agreements was 29 as of March 31, 2026, which includes 12 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.

Total cash, cash equivalents and investments were $147.7 million as of March 31, 2026.

Full Year 2026 Guidance

Full year revenue expected to be $30 million to $32 million consisting of:

Core revenue of $25 million to $27 million.

SPL Program-related revenue of approximately $5 million for the year; SPL Program-related revenue guidance includes both revenue of approximately $3 million from milestone payments and approximately $2 million from commercial royalties.

MaxCyte expects to end 2026 with at least $136 million in total cash, cash equivalents and investments, which does not include capital to be used for the share repurchase program.

The following tables provide details regarding the sources of our revenue for the periods presented.

Three Months Ended

March 31

(Unaudited)

2026

2025

(in thousands, except percentages)

Instruments

1,346

1,444

(7%)

PAs and consumables

2,293

3,871

(41%)

Licenses

2,097

2,531

(17%)

Assay service

188

142

Other

294

255

Total Core Revenue

6,218

8,243

(25%)

Milestones

3,004

2,004

Royalties

429

143

200

Total Revenue

9,651

10,390

(7%)

Share Repurchase Program

MaxCyte’s board of directors has authorized a share repurchase program for up to $10 million of the Company’s outstanding common stock within a one-year period, unless extended or shortened by the board of directors. Any repurchases would be made in the open market and/or in privately negotiated transactions, and may be made from time to time or in one or more larger repurchases. Repurchases may be made pursuant to one or more trading plans adopted in accordance with Rule 10b5-1, through discretionary open market purchases during periods when the Company's trading window is open, and/or in privately negotiated transactions. Open market purchases are expected to be made in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended.

The Company expects to utilize a majority of the approved $10 million in the short to medium term, however, the amount and timing of any repurchases made under the repurchase program will depend on a variety of factors, including available liquidity, cash flow and market conditions. The program does not obligate the Company to acquire any particular amount of common stock and the program may be modified or suspended at any time at the Company’s discretion.

Webcast and Conference Call Details

MaxCyte will host a conference call today, May 12, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

Non-GAAP Financial Measures

This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses these non-GAAP measures to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

This press release also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability.

Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents these Non-GAAP financial measures along with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Reconciliation tables of net loss, the most comparable GAAP financial measure, to EBITDA, and Gross Margin, the most comparable GAAP financial measure, to Non-GAAP Gross Margin, are included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those described in Item 1A under the heading “Risk Factors” and elsewhere in our report on Form 10-K, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, customer expectations and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," “seek,” "predict," “future,” "project," "potential," "continue," “contemplate,” "target,” the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, our full year 2026 revenue, gross margin and cash guidance, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; expectations regarding customer-level activities (including the expected advancement of our SPL partners' clinical programs, including Phase 3 trial initiations); the timing and amount of any share repurchases under our share repurchase program; our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.

These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

ir@maxcyte.com

Media Contact

Oak Street Communications

Kristen White

kristen@oakstreetcommunications.com

415.608.6060

MaxCyte, Inc.

Unaudited Consolidated Balance Sheets

(in thousands, except share and per share amounts)

March 31, 2026

December 31, 2025

Assets

Current assets:

Cash and cash equivalents

14,557

20,065

Short-term investments, at amortized cost

92,297

82,979

Accounts receivable, net

4,246

3,503

Inventory

7,631

7,547

Prepaid expenses and other current assets

4,206

4,275

Total current assets

122,937

118,369

Investments, non-current, at amortized cost

40,811

52,570

Property and equipment, net

16,637

17,531

Right-of-use asset - operating leases

10,699

10,920

Intangible assets, net

783

650

Other assets

2,606

2,467

Total assets

194,473

202,507

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

1,196

1,401

Accrued expenses and other

4,371

7,812

Operating lease liability, current

1,374

1,456

Deferred revenue, current portion

3,271

3,598

Total current liabilities

10,212

14,267

Operating lease liability, net of current portion

16,113

16,487

Other liabilities

262

263

Total liabilities

26,587

31,017

Commitments and contingencies

Stockholders’ equity

Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2026 and December 31, 2025

—

Common stock, $0.01 par value; 400,000,000 shares authorized, 107,121,672 and 106,789,618 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

1,071

1,068

Additional paid-in capital

433,048

431,905

Accumulated deficit

(266,233)

(261,483)

Total stockholders’ equity

167,886

171,490

Total liabilities and stockholders’ equity

194,473

202,507

MaxCyte, Inc.

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share amounts)

Three Months Ended March 31,

2026

2025

Revenue

9,651

10,390

Cost of goods sold

1,569

1,497

Gross profit

8,082

8,893

Operating expenses:

Research and development

3,857

5,903

Sales and marketing

3,428

5,698

General and administrative

5,966

8,526

Depreciation and amortization

1,016

1,061

Total operating expenses

14,267

21,188

Operating loss

(6,185)

(12,295)

Other income:

Interest income

1,435

2,034

Total other income

1,435

2,304

Net loss

(4,750)

(10,261)

Basic and diluted net loss per share

(0.04)

(0.10)

Weighted average shares outstanding, basic and diluted

106,875,087

105,950,480

MaxCyte, Inc.

Unaudited Consolidated Statements of Cash Flows

(in thousands)

Three months ended March 31,

2026

2025

Cash flows from operating activities:

Net loss

(4,750)

(10,261)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

1,047

1,096

Lease right-of-use asset amortization

221

181

Net book value of consigned equipment sold

—

Loss on disposal of property and equipment

—

Stock-based compensation

1,141

3,039

Change in excess/obsolete inventory reserve

197

Amortization of discounts on investments

(437)

(884)

Changes in operating assets and liabilities, net of effects of acquisition:

Accounts receivable

(743)

(839)

Inventory

(380)

531

Prepaid expense and other current assets

Other assets

(127)

(254)

Accounts payable, accrued expenses and other

(3,637)

(5,589)

Operating lease liability

(456)

(278)

Deferred revenue

(327)

(1,326)

Other liabilities

(1)

(4)

Net cash used in operating activities

(8,169)

(14,411)

Cash flows from investing activities:

Purchases of investments

(25,122)

(34,645)

Maturities of investments

28,000

46,600

Purchases of property and equipment

(72)

(653)

Acquisition of intangible assets

(150)

—

Acquisition of business, net of cash acquired of $541

—

(1,773)

Net cash provided by investing activities

2,656

9,529

Cash flows from financing activities:

Proceeds from exercise of stock options

383

Net cash provided by financing activities

383

Net decrease in cash and cash equivalents

(5,508)

(4,499)

Cash and cash equivalents, beginning of period

20,065

27,884

Cash and cash equivalents, end of period

14,557

23,385

Unaudited Reconciliation of Net Loss to EBITDA

(in thousands)

(Unaudited)

Three Months Ended

March 31,

2026

2025

(in thousands)

Net loss

(4,750)

(10,261)

Depreciation and amortization expense

1,047

1,096

Interest income

(1,435)

(2,034)

Income taxes

—

EBITDA

(5,138)

(11,199)

Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted gross margin

(in thousands, except for percentages)

(Unaudited)

Three months ended March 31, 2026

Three months ended March 31, 2025

GAAP

Adjustments

Non-GAAP

GAAP

Adjustments

Non-GAAP

Revenue

9,651

(3,433)

6,218

10,390

(2,147)

8,243

Cost of Goods Sold

1,569

(197)

1,372

1,497

(65)

1,432

Gross Margin

8,082

(3,236)

4,846

8,893

(2,082)

6,811

Gross Margin %

(1)

Adjustments include the exclusion of SPL program related revenue from Revenue, and the exclusion of reserves for excess and obsolete inventory from Cost of Goods Sold.

EX-99.2

Filename: mxct-20260512xex99d2.htm · Sequence: 3

Exhibit 99.2

are trademarks of MaxCyte, Inc. in the U.S.A.

Driving the Next Generation of

Cell-Based Therapies

MaxCyte Corporate Presentation

NASDAQ: MXCT

May 2026

Forward Looking Statement Disclaimer

Certain statements in this document (this “Presentation”) are, or may be deemed to be, forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including

but not limited to statements regarding our expected potential future revenue. These statements about us and our industry involve substantial known and unknown risk, uncertainties and assumptions, that may cause our actual

results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts

contained in this Presentation are forward-looking statements. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project,"

"potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this

Presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or

implied by any forward-looking statements contained in this Presentation, including, without limitation, statements regarding the Company's future growth, results of operations, performance, future capital and other expenditures

(including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. These and other risks and uncertainties are described in greater detail in the section entitled "Risk

Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and

Exchange Commission from time to time. These documents are available, without charge, on the Securities and Exchange Commission website and through the Investor Menu, Financials section under "SEC filings" on the Investors

page of our website at http://investors.maxcyte.com.

No statement in this Presentation is intended to be, or intended to be construed as, a profit forecast or profit estimate or to be interpreted to mean that earnings per Company share for the current or future financial years will

necessarily match or exceed the historical earnings per Company share. As a result, no undue reliance should be placed on such statements.

Any forward-looking statements represent our views only as of the date of this Presentation and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any

forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such

forward-looking statements.

This Presentation contains Adjusted EBITDA, which is a non-GAAP measure defined as earnings before interest, taxes, depreciation, amortization, goodwill impairment and one-time restructuring charges. MaxCyte believes that

Adjusted EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses these non-GAAP measures to compare the company’s performance to that of prior

periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in

comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by

management in its financial and operational decision-making.

This Presentation also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which

can vary significantly between periods and thus affect comparability. Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP.

The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company’s financial statements. Non-GAAP measures should be

considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of Gross Margin, the most comparable GAAP financial measure to

Non-GAAP Gross Margin, is included in the appendix of this Presentation. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate its business.

MaxCyte at a Glance

Our Mission

We power the future of cell and gene

therapy with innovative, scalable cell

engineering solutions that enable our

customers to deliver advanced

therapies to patients

Base-editing (CRISPR),

CRISPR, ARCUS, RNA-Based

Engineering, TALENS, Zinc

Finger Nucleases (ZFNs)

Clinical and Commercial

Therapies Supported

2025

Revenue

• Genetic diseases, solid

tumors, infectious disease,

Hematological

• Malignancies, autoimmune

disease

SPL Customers

$148M

Cash & Cash Equivalents1

$33.0M

2025 Non-GAAP

Adjusted Gross Margins 81% 2

1. As of March 31, 2026

2. Excluding SPL Program-related revenue and reserves for

excess and obsolete inventory. See appendix for reconciliation

to GAAP gross margins

Cell and Gene Therapy Development

Cell Engineering

(Electroporation)

Cell Proliferation

In-Vivo Ex-Vivo

Viral/Non-Viral

Vector for delivery

to Specific Organ

Tissue

The engineering of cells to develop therapies addressing a host of human diseases with unmet medical needs

Cells Collected

from Universal

Donor or Patient

Personalized Therapy

Cryopreservation

Patient

Cell & Gene Therapy is one of the

fastest growing and most

promising treatment modalities

~2,130 active clinical trials focused on

as of Dec 2025*

Aggregate of $11.1B raised in 2025*

Genetic diseases, solid tumors,

infectious disease, hematological, and

autoimmune

48 approved cell and gene therapies**

*Alliance for Regenerative Medicine (“ARM”) as of Dec 2025

**FDA approved Cellular and Gene Therapy Products

Addressing the Challenges of Cell & Gene Therapy

Development

Next-generation cell therapy programs have become increasingly complex requiring multiple edits

Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications)

Vein-to-vein manufacturing times are high; optimizations needed to deliver medicines to patients faster

Lack of industry standard for cell engineering process development causes costly and inconsistent

manufacturing runs

Many steps in the cell engineering process with lack of support or safety assessments before

regulatory review

Large Opportunity in Ex-Vivo Cell and Gene Therapy

MaxCyte # of Potential SPLs

Research &

Discovery

Pre-Clinical

Clinical

Commercial

124 Programs

82 Non-Viral Programs (66%)

383 Programs

193 Non-Viral Programs (50%)

249 Programs

84 Non-Viral Programs (37%)

10 Programs

1 Non-Viral Program (10%)

Ex-Vivo Cell & Gene Therapy TAM

201 Ex-Vivo Cell & Gene

Therapy Biotechs

83 Non-Viral

Ex-Vivo Cell & Gene

Therapy Biotechs

Gene Editing Tools:

• ARCUS

• Base-editing (CRISPR)

• Prime-editing (CRISPR)

• CRISPR

• RNA-Based Engineering

• Transposon

• TALENS

• Zinc Finger Nucleases

(ZFNs)

Source: MaxCyte Company Estimates for

U.S. and EU Markets

Programs with undisclosed vector are

assumed to be Viral and Non-Viral at the

market concentration ratio of 53% to 47%,

respectively

The Expert Platform Enabling Non-Viral Cell Engineering

Full scale

RUO

Small/mid-scale

RUO

Large Scale

RUO/cGMP

Full scale

RUO/cGMP

75 thousand to

700 million cells

75 thousand to

20 billion cells

5 billion to

200 billion cells

75 thousand to

20 billion cells

High Performance

• >90% transfection efficiencies

(depending on cell type and

molecule)

• >90% cell viabilities

• Computer-controlled system for

reproducible results

Flexibility

• Single, fully-defined, animal

component-free electroporation

buffer for all cell types

• Pre-loaded library of validated,

cell-specific protocols

Scalability – Ability to Transfect

• 75,000 to 7 million cells in seconds

• Up to 20 billion cells in less than 30

minutes

• And up to 200 billion cells in less than 30

minutes with the high scale VLx

High Quality

• Sterile, single-use processing

assemblies (PAs)

• Closed, cGMP-compliant, ISO-certified, and CE marked instruments

• Supported by US FDA Master File and

global equivalents

Key Applications: Ex-Vivo Engineered Cell Therapies

Customer Base: Leading global cell therapy developers

and academic translational centers

Additional

Electroporation

Applications in

Drug Discovery

Viral Vector Production – Transfect

adherent or suspension cells to produce

a variety of viral vectors.

Cell Based Assays – Produce

assay-ready cells faster with

scalable electroporation.

Gene Editing – Navigate the

complexities of genome engineering

with highly efficient delivery.

Antibody & Protein Production – Accelerate

biotherapeutic development with transient

expression for gram-scale protein production.

Vaccine Development – Innovate vaccine

research with our adaptable platform for

production of recombinant proteins, virus-like

particles and more.

Research & discovery

96-well platform

RUO

100 thousand to

10 million cells

Launched Q1-26

Instrument purchase &

research scale

GMP: 25µL – 100mL on GTx

21 CFR Part 11 Compliant

MaxCyte’s Solutions Span Cell & Gene Engineering

Industry-leading, scalable Expert Electroporation Platform and best-in-class customer support

Commercial

Strategic platform license for clinical &

commercial manufacturing

IND-enabling

lease

Discovery Process Development IND-enabling activities IND-enabling study / Clinical

IND filing BLA filing

Instrument

purchase & full

scale with flow EP

RUO RUO GMP GMP

Screening Validation Lead ID Concept Discovery Optimization Verification

RUO: 25µL – 3.5mL on DTx

RUO: 25µL – 3.5mL on ATx

RUO: 25µL – 100mL on STx

Strategic platform license for large allogeneic manufacturing

GMP: 25µL – 1L on VLx

21 CFR Part 11 Compliant

GMP

MaxCyte’s Flow Electroporation® technology integrates

efficiently within a closed cGMP cell therapy workflow

Cell Isolation & Expansion CCBE Electroporation Cell Expansion Cryopreservation

Add loading agent

(mRNA, pDNA, RNP…)

and Electroporate

Process cells on

different platforms

Wash media and exchange

from different platforms to

MaxCyte Buffer

Infusion and

cryopreservation

Seamlessly scale

from initial cell

therapy concept to

commercialization

• Leverages the reversible permeability of the cell membrane in response to an electric charge

• Universally delivers molecules, such as nucleic acids, gene-editing tools and proteins, into cells

• Agnostic to cell type, approach (auto/allo) and/or gene manipulation technology

• Supported by a robust intellectual property portfolio (200+ patents granted in US and foreign jurisdictions

and 100+ patents pending worldwide)

• Enables customers to use a single platform from concept through to the clinic in a GMP environment

• >100 protocols optimized through 25 years of research by experts in biophysics, biochemistry and cell biology

Development of Ex Vivo Cell Therapies Requires Highly

Specialized Engineering Tools and Assays

Lentivirus

Adeno-associated

virus

Lipid

nanoparticles

Electroporation

Engineering

Tools

Delivery

Technologies

CRISPR/Cas

gene editing

Transposase

integration

mRNA transient

expression

Stable DNA

transduction

Engineered

Cell Therapy Starting Cell

Material

Post-engineering analyses:

• On-target editing confirmation

• Off-target editing risk assessment

• Cell functional assays

• Cell phenotype characterization

Engineering Strategies

Pre-engineering analyses:

• Cell health determination

• Cell purity characterization

• Cell identity confirmation

 Single alteration vs. multiple alterations

 Sequential engineering vs. simultaneous engineering

 Integrating vs. non-integrating approaches

Developing engineering ex vivo cell therapies is highly complex

MaxCyte’s Solutions are Uniquely Positioned

to Support Cell Therapy Development

Flow Electroporation technology facilitates multiplex and sequential engineering without the

payload and capacity limitations of viral approaches

23+1 Field Application Scientists support our customers in their development process

Expert platform provides industry leading transfection efficiency & cell viability at high scale

in 30 minutes or less, enabling manufacturers to quickly scale up production

Regulatory

Support

Superior

Results

Complex

Engineering

Optimization

Scientific

Support

FDA Master File can be referenced in regulatory filings to accelerate and de-risk regulatory

review

MaxCyte technology allows plug and play processes with rapid optimization delivering reproducible

outcomes and the ability to seamlessly scale up from pre-IND to the clinic and commercialization

1. As of December 31, 2025

MaxCyte’s Platform Generates Recurring Revenue

in Pre-Clinical, Clinical, and Commercial

Razor/Razor Blade Economics

Full scale

RUO

Preclinical and Academic Revenue Model

Instrument Sale

Clinical and Commercial Revenue Model

Annual License Fee

Razor/Razor Blade Economics

+ Share of Therapeutic Economics

Clinical Milestones and Commercial

Royalties/Sales Based Payments

Single-use

Disposables (PAs)

Full scale

GMP

Single-use

Disposables (PAs)

+ +

MaxCyte captures unique economic participation in customers success as a result of

its proven technology and differentiated technical, scientific, and regulatory support

Lyell

Immunopharma

MaxCyte has an Active Portfolio of SPLs

29 SPL Partners1

Sana

Biotechnology

Beam

Therapeutics

cGMP Compatible

Platform

FDA Master File and

Technical Files

Experienced FAS and

sales support

Leading know-how and

engineering process

improvement

12 Active Clinical Programs Represents ~$110M of precommercial milestone potential

>$30M of milestone payments to date through SPL model

Updated as of May 2026

1. Catamaran Bio and Walking Fish Therapeutics have ceased

operations, resulting in 29 SPLs

2. Cleared INDs or Equivalent

3. Editas Medicine, Myeloid, and Vor Biopharma have announced

their exit of the ex-vivo space

8 SPL partners in preclinical

18 preclinical programs

11 SPL partners in clinical

12 clinical programs2

10 SPL partners in research3

1 Commercial Program

Typical MaxCyte SPL Economics

Early Clinical: (Phase 1/2) Years 1-3

• Mid 6-figure up to low 7-figure milestones

• 1-3+ instruments + disposables

Mid-late Clinical: (Phase 2/3) Years 3-5+

• 7-figure milestone

• Increasing instrument and disposables usage

Approval: Year 5+

• Multiple 7-figure milestones based on

geographic region (e.g. US and Europe)

Commercial Phase

• Royalty and/or sales-based payments

• Annual instrument fees and

disposable sales

Instruments and

Processing Assemblies

Milestones

Royalties & Sales-Based

Payments

Pre-commercial milestones

in early clinical, mid-late

clinical and product approval

Significant development

milestones and high-value

participation in future

commercial success of partners

Recurring revenues from lease

of instruments and sales of

single-use disposables

Royalites and Sales-based

payments upon partner’s

product commercialization

Differentiated Commercial Relationships

Expand Sales Funnel

Highly Technical Employees Field Application Scientists (FAS) and Commercial Team

Unparalleled

scientific support

to customers

Customer relationships

at early stages of cell

& gene therapy

development

Signed

SPL

*Updated as of December 31, 2025

MaxCyte has a team of

23+ highly trained FAS*

Global teams providing

scientific, technical, and

regulatory expertise FAS works with prospective customers to optimize and

implement cell engineering methods, processes, and applications

MaxCyte grows its sales funnel by leading with scientific, technical, and regulatory expertise

50 Advanced Degrees

and 23 PhDs*

Support academic and translational

institutions, biotech companies,

and pharma companies in

discovery and pre-clinical

As of March 2026/ Includes with SPL Programs with multiple Clinical Trials for different indications

SPL Portfolio: 14 Active Clinical Trials

Partner Program Phase Cell Approach Cell Type Disease Area

Vertex Pharmaceuticals CASGEVY Commercial Autologous HSCs Beta-thalassemia

Vertex Pharmaceuticals CASGEVY Commercial Autologous HSCs Sickle cell disease

Wugen WU-CART-007 Pivotal Allogeneic T-Cells T Cell Lymphoma

Undisclosed Partner A - Pivotal Undisclosed Undisclosed Undisclosed

CRISPR Therapeutics CTX112 1/2 Allogeneic T-Cells Hematological Malignancies

CRISPR Therapeutics CTX112 1/2 Allogeneic T-Cells Autoimmune Disease

Imugene Azer-cel 1/2 Allogeneic T-Cells Hematological Malignancies

Kamau Therapeutics Nula-Cel 1/2 Autologous HSCs Sickle Cell Disease

KSQ Therapeutics KSQ-001EX 1/2 Autologous TILs Advanced Solid Tumors

KSQ Therapeutics KSQ-004EX 1/2 Autologous TILs Advanced Solid Tumors

TG Therapeutics Azer-cel 1 Allogeneic T-Cells Multiple Sclerosis

Vittoria Biotherapeutics VIPER-101 1 Autologous T-Cells T-Cell Lymphoma

Undisclosed Partner B - 1 Undisclosed Undisclosed Undisclosed

Undisclosed Partner C - 1 Undisclosed Undisclosed Undisclosed

SPL Case Study: CASGEVY®

CASGEVY® for Sickle Cell Disease (SCD) and for Transfusion-Dependent Beta-Thalassemia (TDT) (2023 and 2024)

2013 – MaxCyte supports

Inception Genomics

(Changed name to CRISPR Therapeutics AG in 2014)

• Support for programs in research

2018 – Vertex/CRISPR

achieves IND Milestone

Sept 28, 2022 – MaxCyte Signs

SPL with Vertex to advance Exa-cel

• Vertex obtains non-exclusive clinical and commercial

rights to use MaxCyte’s Expert platform

Dec 8, 2023 – FDA

Approves CASGEVY®

(for treatment of SCD)

2021 – Vertex initiated

Pivotal Trial for CASGEVY®

Jan 16, 2024 – FDA Approves

CASGEVY®

(for treatment of TDT)

Feb 12, 2024 – European

Commission Approves

CASGEVY®

(for treatment of SCD and TDT)

Nov 15, 2023 – UK MHRA

Approves CASGEVY®

(for treatment of SCD and TDT)

CASGEVY®

Jan 9, 2024 – SFDA

Approves CASGEVY®

(for treatment of SCD and TDT)

MaxCyte Supports the Future of Cell & Gene Therapies

WAVE 1

1 Approved Product

WAVE 2

5 Product Candidates

WAVE 3

7 Product Candidates

WAVE 4

18 Product Candidates

Vertex/ CRISPR

CASGEVY®

Approved 2023

US FDA, European

Commission & Additional

Regulatory Bodies

Launch Potential:

2027 – 2028

5 products set to

enter pivotal studies

in next 6 to 18

months

Launch Potential:

2028 +

7 products currently

in Phase 1

Launch Potential:

2032 +

18 products in

preclinical development

Source: Evaluate Pharma, Broker Estimates and MaxCyte Internal Estimates as of March 2026

MaxCyte’s supports a diverse portfolio of product candidates with significant

development milestone and commercial royalty potential

MaxCyte’s Roadmap to Becoming a Premier

Cell Engineering Solutions Providers

Electroporation

technology provider

Comprehensive cell

engineering solutions

Gene Editing Tools

Over $1.25b market

• Key markets addressed: in vivo

and ex vivo cell therapy

• Other key markets addressed:

Agbio, bioprocessing, research

and discovery tools

Genetic Payloads

(i.e. gene insertion/expression)

Over $6.0b market

• Key markets addressed: in vivo and

ex vivo cell therapy

• Other key markets addressed:

vaccines, bioprocessing, research

and discovery tools

Other Biological Delivery

Over $4.0b market

• Key markets addressed: in vivo

and ex vivo cell therapy

• Other key markets addressed:

vaccines, bioprocessing, research

and discovery tools

Cell engineering

risk assessment

Organic and Inorganic Investment

• Product Development

• Acquisitions

• Licensing Deals

• Distribution Deals

Source: Internal analysis

Editing Assessment Services Strategy

MaxCyte provides ex-vivo and in-vivo developers with best-in-class on-target and off-target risk assessment services

Use Cases: candidate guide

screening, guide RNA selection

Use Cases: Off-target risk assessment,

guide RNA selection, IND filings

 Highly sensitive

 Universal for all

editors

 Population-scale variant

assessment

 Multiple orthogonal

methods

 Variant effect

prediction

 GLP-grade

Guide Screening

 Rapid turnaround

time

 Comprehensive

report

 Minimize risk from

variation at on-target locus

Guide RNA Selection

 Low-cost per guide

 Evaluate multiple

guides

 Reduce program

risk through early

profiling and

selection

Use Cases: Cellular Editing

Assessment, IND filings

 Sensitive detection

methods

 Relevant cell types

 On- and off-target

analysis

 Biologic impact

assessment

 GLP-grade

 Increases program likelihood of success

 Decreases risk of unexpected costs or program delays

 Aligns with most recent FDA guidance for gene edited therapies

 Quicker time to clinic and safer therapies

Discovery Pre-Clinical Development and IND-Enabling Studies

BENEFITS

Financial Summary

$1.4 $1.3

$3.9

$2.3

$2.5

$2.1

$0.1

$0.2

$0.3

1Q25 1Q26

Core Revenue:

(25%) Decline

$7.1 $6.8

$14.0 $11.9

$10.3 $8.9

$1.1 $1.2

$6.1

$3.4

2024 2025

Core Revenue:

(9%) Decline

1. Excluding SPL Program-related revenue and reserves

for excess and obsolete inventory. See appendix for

reconciliation to GAAP gross margins

Financial Highlights (As of March 31, 2026)

78%

Non-GAAP adjusted Gross Margin1

44%

Core revenue generated from SPL

partners as a % of core revenue

877

Total Installed Base of Instruments

(sold or licensed)

$148 million

Total cash, cash equivalents,

and investments

Total Annual Revenue (millions)

Core Revenue

Total Quarterly Revenue (millions)

Core Revenue

$38.6

$33.0

$9.7 $10.4

$2.1

$0.8

$3.4

Financial Summary

In millions, except percentages 2024 2025 YTD 2026

Total Core Revenue $32.5 $29.6 $6.2

y/y growth 9% (9%) (25%)

SPL-Program Related Revenue $6.1 $3.4 $3.4

y/y growth (47%) (44%) 60%

Total Revenue $38.6 $33.0 $9.7

y/y growth (6%) (15%) (7%)

Gross Profit $31.5 $26.8 $8.1

Gross Margin % 82% 81% 84%

Non-GAAP Adjusted Gross Margin %1 84% 81% 78%

Operating Expenses $82.7 $78.7 $14.3

Net Income (Loss) ($41.1) ($44.6) ($4.8)

EBITDA2 ($47.6) ($46.9) ($5.1)

Full Year Ended December 31,

1. Excluding SPL Program-related revenue and reserves for excess and obsolete inventory. See appendix for reconciliation to GAAP gross margins

2. See appendix for Unaudited Reconciliation of Net Loss to EBITDA

3 months

Disciplined Management is Committed to Growth Investment

and Efficient Spending

MaxCyte is well

capitalized and funded

to achieve profitability

with existing capital

Alignment of spending and

resources to growth areas

Organic investment

in new products and

product enhancements

Reduction of annual cash

burn excluding one-time

and non-cash items

Realize operating leverage

on existing cost base

Inorganic investment to

solve critical pain points in

Cell & Gene Therapy

Healthy balance sheet

~$148M of cash, cash

equivalents, and investments1

1. As of March 31, 2026

All other trademarks are the property of their respective owners.

list of MaxCyte trademarks in the United States and

other countries, please visit maxcyte.com/trademarks.

Thank you!

Any questions?

ir@maxcyte.com

Appendix – Historical Core Business Disclosure

1Q'22 2Q'22 3Q'22 4Q'22 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q’24 3Q’24 4Q’24 1Q’25 2Q’25 3Q’25 4Q’25 1Q’26

(in $ thousands)

Instrument 2,728 2,697 2,575 3,705 2,189 2,126 1,672 2,330 1,928 1,762 1,764 1,629 1,444 2,141 1,376 1,841 1,346

PAs 3,840 4,114 4,350 3,721 2,600 3,293 2,226 2,163 3,432 2,974 3,432 4,169 3,871 3,128 2,577 2,312 2,293

Licenses 2,726 2,622 2,736 2,813 2,809 2,667 2,444 2,406 2,604 2,610 2,528 2,554 2,531 2,619 1,803 1,993 2,097

Assay service - - - - - - - - - - - - 142 51 248 335 188

Other 290 171 227 331 174 203 258 263 224 229 416 258 255 259 402 274 294

Total Core Revenue 9,583 9,604 9,889 10,570 7,772 8,289 6,600 7,162 8,188 7,575 8,140 8,610 8,243 8,198 6,406 6,755 6,218

Installed base of instruments (sold or leased) 521 546 575 616 633 654 664 683 708 723 739 760 787 814 830 857 877

Core Revenue Generated by SPL Clients as a %

of Core Revenue 47% 47% 40% 34% 52% 49% 45% 45% 53% 51% 53% 55% 57% 42% 53% 36% 44%

Appendix – Unaudited Reconciliation of Gross Margin

to Non-GAAP Adjusted gross margin

1. Adjustments include the exclusion of SPL program related revenue from Revenue, and the exclusion of reserves for excess and obsolete inventory from Cost of Goods Sold.

Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted gross margin

(in thousands, except for percentages)

(Unaudited)

Three months ended March 31, 2026 Three months ended March 31, 2025

GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP

Revenue $ 9,651 $ (3,433) $ 6,218 $ 10,390 $ (2,147) $ 8,243

Cost of Goods Sold 1,569 (197) 1,372 1,497 (65) 1,432

Gross Margin 8,082 (3,236) 4,846 8,893 (2,082) 6,811

Gross Margin % 84% 78% 86% 83%

Appendix – Unaudited Reconciliation of Net Loss to Adjusted

EBITDA

Unaudited Reconciliation of Net Loss to Adjusted EBITDA

(in thousands)

(Unaudited)

Three Months Ended

March 31,

2026 2025

(in thousands)

Net loss $ (4,750) $ (10,261)

Depreciation and amortization expense 1,047 1,096

Interest income (1,435) (2,034)

Income taxes — —

EBITDA $ (5,138) $ (11,199)

GRAPHIC

Filename: mxct-20260512xex99d1001.jpg · Sequence: 4

Binary file (7633 bytes)

Download mxct-20260512xex99d1001.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g001.jpg · Sequence: 5

Binary file (88445 bytes)

Download mxct-20260512xex99d2g001.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g002.jpg · Sequence: 6

Binary file (288059 bytes)

Download mxct-20260512xex99d2g002.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g003.jpg · Sequence: 7

Binary file (146140 bytes)

Download mxct-20260512xex99d2g003.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g004.jpg · Sequence: 8

Binary file (161799 bytes)

Download mxct-20260512xex99d2g004.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g005.jpg · Sequence: 9

Binary file (133324 bytes)

Download mxct-20260512xex99d2g005.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g006.jpg · Sequence: 10

Binary file (148196 bytes)

Download mxct-20260512xex99d2g006.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g007.jpg · Sequence: 11

Binary file (209620 bytes)

Download mxct-20260512xex99d2g007.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g008.jpg · Sequence: 12

Binary file (151883 bytes)

Download mxct-20260512xex99d2g008.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g009.jpg · Sequence: 13

Binary file (206366 bytes)

Download mxct-20260512xex99d2g009.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g010.jpg · Sequence: 14

Binary file (171112 bytes)

Download mxct-20260512xex99d2g010.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g011.jpg · Sequence: 15

Binary file (158040 bytes)

Download mxct-20260512xex99d2g011.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g012.jpg · Sequence: 16

Binary file (177705 bytes)

Download mxct-20260512xex99d2g012.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g013.jpg · Sequence: 17

Binary file (184941 bytes)

Download mxct-20260512xex99d2g013.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g014.jpg · Sequence: 18

Binary file (145874 bytes)

Download mxct-20260512xex99d2g014.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g015.jpg · Sequence: 19

Binary file (168297 bytes)

Download mxct-20260512xex99d2g015.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g016.jpg · Sequence: 20

Binary file (180800 bytes)

Download mxct-20260512xex99d2g016.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g017.jpg · Sequence: 21

Binary file (168931 bytes)

Download mxct-20260512xex99d2g017.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g018.jpg · Sequence: 22

Binary file (153936 bytes)

Download mxct-20260512xex99d2g018.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g019.jpg · Sequence: 23

Binary file (176017 bytes)

Download mxct-20260512xex99d2g019.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g020.jpg · Sequence: 24

Binary file (177594 bytes)

Download mxct-20260512xex99d2g020.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g021.jpg · Sequence: 25

Binary file (137744 bytes)

Download mxct-20260512xex99d2g021.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g022.jpg · Sequence: 26

Binary file (136871 bytes)

Download mxct-20260512xex99d2g022.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g023.jpg · Sequence: 27

Binary file (154305 bytes)

Download mxct-20260512xex99d2g023.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g024.jpg · Sequence: 28

Binary file (70255 bytes)

Download mxct-20260512xex99d2g024.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g025.jpg · Sequence: 29

Binary file (132138 bytes)

Download mxct-20260512xex99d2g025.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g026.jpg · Sequence: 30

Binary file (108233 bytes)

Download mxct-20260512xex99d2g026.jpg

GRAPHIC

Filename: mxct-20260512xex99d2g027.jpg · Sequence: 31

Binary file (90754 bytes)

Download mxct-20260512xex99d2g027.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 36

v3.26.1

Document and Entity Information

May 12, 2026

Document and Entity Information [Abstract]

Document Type

8-K

Document Period End Date

May 12, 2026

Entity File Number

001-40674

Entity Registrant Name

MaxCyte, Inc.

Entity Incorporation, State or Country Code

Entity Tax Identification Number

52-2210438

Entity Address State Or Province

Entity Address, Address Line One

9713 Key West Avenue

Entity Address, Adress Line Two

Suite 400

Entity Address, City or Town

Rockville

Entity Address, Postal Zip Code

20850

City Area Code

301

Local Phone Number

944-1700

Title of 12(b) Security

Common Stock, $0.01 par value

Trading Symbol

MXCT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

Entity Central Index Key

0001287098

Amendment Flag

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration